Cetuximab (PBS) is a humanized monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR . Cetuximab (PBS) exhibits potent antitumor activity and is utilized in biomedical research focused on EGFR signaling inhibition, receptor tyrosine kinase regulation, and antibody-mediated targeting of EGFR-expressing cellular systems in oncology model frameworks.